Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesBeam Therapeutics Inc

Beam Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
24.75 USD -1.06 ( 4.11%)
Last update at 2026-11-12T15:43:00Z
VOLUME
236696
Market Cap
3153.27M

Momentum Score

…

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
24.29
Low
25.15
High
52 Week Price Range
15.35
Low
36.44
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Beam Therapeutics develops precision genetic medicines using base editing, a platform designed to make specific single-base DNA changes without introducing double-strand breaks. Its long-term growth drivers include platform expansion into both ex vivo and in vivo programs, progression of a diversified pipeline toward clinical proof-of-concept, and intellectual property around novel editors. Investors may find the company attractive because the technology appears positioned to address multiple monogenic diseases with an aim to improve safety and specificity versus earlier gene-editing approaches.
Principal risks are clinical and regulatory uncertainty, potential off-target or long-term safety issues unique to base editing, substantial cash burn and financing needs, and strong competition from other gene-editing and genetic-medicine developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
25.81
Dividend Yield
-
Revenue TTM
139.74M
Revenue Per Share
1.41
Gross Profit TTM
-269.88M
Debt / Equity
0.24
ROE
-8.11%
Net Debt
-1.06M
ROCE
-2.62%
Diluted EPS TTM
-0.81

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -79.99M -376.70M -131.16M -260.18M -370.64M
Net income -79.99M -376.74M -132.53M -263.59M -341.36M
Selling general administrative 113.82M 111.53M 116.81M 87.81M 57.22M
Selling and marketing expenses - - 20.01M - -
Gross profit 117.45M -304.04M 377.71M 60.92M 51.84M
Reconciled depreciation 22.29M 31.59M 18.59M 14.15M 7.45M
Ebit -36.26M -415.57M -176.49M -338.48M -392.46M
Ebitda -29.92M -393.64M -146.95M -401.48M -414.30M
Depreciation and amortization 6.34M 21.93M 29.53M -63.00M -21.84M
Non operating income net other - - - - 21.83M
Operating income -383.69M -415.57M -176.49M -338.48M -392.46M
Other operating expenses 523.44M 479.09M 554.19M 399.40M 444.31M
Interest expense 43.73M 49.09M 46.68M 15.30M 0.01M
Tax provision 0.00M 0.04M 1.00M 3.41M -
Net interest income 43.73M 49.09M 42.22M 15.30M -0.01M
Income tax expense - 0.04M 1.37M 3.41M -29.28M
Total revenue 139.74M 63.52M 377.71M 60.92M 51.84M
Total operating expenses 501.14M 111.53M 554.19M 399.40M 444.31M
Cost of revenue 22.29M 367.56M 437.38M - -
Total other income expense net 303.70M 38.87M 45.32M 78.30M 21.83M
Net income from continuing ops -79.99M -376.74M -313.67M -289.09M -370.64M
Net income applicable to common shares - - - -260.18M -370.64M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1481.18M 1103.82M 1459.71M 1341.71M 1474.45M
Other current assets 23.48M 27.41M 21.17M 14.76M 307.36M
Total liab 242.82M 370.28M 478.38M 608.24M 647.72M
Total stockholder equity 1238.36M 733.54M 981.33M 733.47M 826.74M
Other current liab 65.68M 37.78M 121.98M 68.21M 112.15M
Common stock 1.02M 0.84M 0.82M 0.71M 0.68M
Capital stock 1.02M 0.84M 0.82M 0.71M 0.68M
Retained earnings -1641.22M -1566.63M -1189.89M -1057.36M -768.27M
Other liab - - - 214.87M 296.46M
Other assets - - - 14.69M 14.47M
Cash 294.94M 281.97M 435.89M 232.77M 965.65M
Total current liabilities 96.94M 182.07M 205.56M 223.59M 213.44M
Current deferred revenue 6.66M 108.86M 68.71M 135.97M 86.27M
Net debt -1.06M -120.54M -262.72M -53.76M -823.30M
Short term debt 14.36M 13.47M 13.26M 10.38M 7.54M
Short long term debt - - - - 2.29M
Short long term debt total 293.88M 161.43M 173.17M 179.00M 142.35M
Other stockholder equity 2877.45M 2298.66M 2169.80M 1792.55M 119.92M
Property plant equipment - - - 234.13M 186.98M
Total current assets 1268.69M 878.15M 1211.04M 1092.90M 965.65M
Net tangible assets - - - 733.47M 826.74M
Short term investments 950.27M 568.77M 753.98M 845.37M 405.65M
Net receivables - - - 0.00M 300.00M
Long term debt - - - - 3.01M
Inventory - - - - -607.36M
Accounts payable 10.23M 3.87M 1.62M 9.03M 7.47M
Accumulated other comprehensive income 1.11M 0.68M 0.60M -2.43M -0.05M
Common stock total equity - - - - 0.68M
Retained earnings total equity - - - - -768.27M
Non currrent assets other 0.63M 9.40M 2.15M 14.69M 321.83M
Non current assets total 212.49M 225.68M 248.67M 248.82M 508.81M
Capital lease obligations 154.12M 161.43M 172.69M 179.00M 142.35M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -361.56M 185.01M 87.18M -461.34M -247.95M
Change to liabilities - - - -33.55M 348.97M
Total cashflows from investing activities -121.44M 185.01M 71.84M -461.34M -294.14M
Net borrowings 0.00M -0.48M -2.25M -2.29M -2.12M
Total cash from financing activities 478.05M 7.74M 276.45M 111.59M 756.14M
Change to operating activities - - - -14.82M -237.72M
Net income -79.99M -376.74M -132.53M -289.09M -370.64M
Change in cash 11.51M -154.50M 199.09M -327.22M 395.73M
Begin period cash flow 290.11M 444.61M 245.52M 572.74M 177.01M
End period cash flow 301.62M 290.11M 444.61M 245.52M 572.74M
Total cash from operating activities -345.10M -347.25M -149.19M 22.53M -66.27M
Issuance of capital stock 470.51M 0.00M 268.46M 108.26M 757.45M
Depreciation 22.29M 21.93M 20.01M 14.15M 7.45M
Other cashflows from investing activities 254.75M -8.95M - - 0.62M
Change to account receivables - - -0.15M 300.00M -300.00M
Sale purchase of stock - - - - 758.26M
Other cashflows from financing activities - 8.22M 8.53M 5.62M 0.81M
Change to netincome - - - 16.93M 185.66M
Capital expenditures 14.95M 8.95M 33.73M 48.95M 46.81M
Cash flows other operating - - - - 51.89M
Cash and cash equivalents changes - - - - 395.73M
Change in working capital -131.02M -110.22M -116.45M 251.63M 111.25M
Stock based compensation 94.24M 120.66M 98.65M 84.32M 43.57M
Other non cash items -250.63M -2.87M -18.87M -38.48M 158.86M
Free cash flow -360.05M -356.19M -182.93M -26.42M -113.08M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BEAM
Beam Therapeutics Inc		 -1.06
4.11%		 24.75 - - 22.56 2.59 15.17 -7.03
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

238 Main Street, Cambridge, MA, United States, 02142

857 327 8775

https://beamtx.com

511

Name Title Year Born
Mr. John M. Evans M.B.A. CEO & Director 1978
Dr. Giuseppe Ciaramella Ph.D. Pres & Chief Scientific Officer 1969
Ms. Terry-Ann Burrell M.B.A. CFO & Treasurer 1977
Dr. Feng Zhang Ph.D. Co-Founder NA
Dr. David R. Liu Ph.D. Co-Founder NA
Dr. J. Keith Joung M.D., Ph.D. Co-Founder NA
Dr. Nicole Gaudelli Ph.D. Co-Founder NA
Dr. Alexis Komor Ph.D. Co-Founder NA
Ms. Suzanne Fleming Chief Accounting Officer 1961
Mr. Brian Riley Sr. VP of Technical Operations 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…